ASEAN Point of Care Diagnostics - Company Evaluation Report, 2025
Description
The ASEAN Point of Care Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for ASEAN Point of Care Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 62 companies, of which the Top 15 ASEAN Point of Care Diagnostics Companies were categorized and recognized as quadrant leaders.
The 360 Quadrant maps the ASEAN Point of Care Diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the ASEAN Point of Care Diagnostics quadrant. The top criteria for product footprint evaluation included Product [Infectious Disease Testing Products (HIV Testing Products, Respiratory Infection Testing Products [TB Testing Products, Influenza Testing Products, Other Respiratory Infection Testing Products], Mosquito-borne Disease Testing Products, STD Testing Products, Hepatitis Testing Products [Hepatitis B Testing Products, Hepatitis C Testing Products], HAI Testing Products, Other Infectious Disease Testing Products), COVID-19 Testing Products, Glucose Monitoring Products (Glucose Test Strips, Glucometers, Lancets), Cardiometabolic Testing Products (Cardiac Marker Testing Products, HBA1C Testing Products, Blood Gas & Electrolyte Testing Products), Coagulation Monitoring Products, Pregnancy & Fertility Testing Products, Urinalysis Testing Products, Cancer Marker Testing Products, Cholesterol Testing Products, Hematology Testing Products, Fecal Occult Testing Products, Drugs-of-abuse Testing Products, Other POC Products], Technology [Lateral Flow Assays (Immunoassays), Rapid Tests (Molecular Diagnostics), Biochemistry], End User [Clinical Laboratories, Hospitals and Critical Care Centers, Outpatient Settings and Ambulatory Care Centers, Home Care Settings, Other End Users].
Key Players:
Major vendors in the ASEAN Point of Care Diagnostics market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), and ARKRAY, Inc. (US). The key strategies major vendors implement in the ASEAN Point of Care Diagnostics market are partnerships, collaborations, product launches, and product enhancements.
Abbott
Abbott is a leading diversified global healthcare company with strong market positions in diagnostics, medical devices, nutrition, and established pharmaceuticals. It is renowned for its market-leading Freestyle Libre glucose monitoring system, Alinity diagnostic platforms, and cardiovascular devices. Strategically, Abbott is focused on driving growth through continuous innovation in its medical device and diagnostics portfolios, particularly in diabetes care and structural heart. This approach, combined with its strong presence in emerging markets like India, ensures its continued influence on global health and wellness.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche is a global pioneer in healthcare, uniquely positioned with world-leading divisions in both Pharmaceuticals and Diagnostics. The Swiss company is a powerhouse in oncology and immunology and is the global market leader in in-vitro diagnostics with its cobas® platforms. Roche’s core strategy is ""Personalized Healthcare,"" leveraging insights from its diagnostics business to develop targeted therapies and guide clinical decisions. By combining these synergistic strengths, Roche continues to drive medical innovation and shape the future of individualized patient care worldwide.
Siemens Healthineers AG
Siemens Healthineers is a leading global medical technology company with dominant positions in diagnostic imaging, laboratory diagnostics, and cancer care. Following its transformative acquisition of Varian, the German firm now offers a uniquely comprehensive portfolio, from MRI and CT scanners to advanced radiation therapy systems. Its strategy focuses on integrating these capabilities to create end-to-end solutions, particularly in oncology, while embedding AI across its platforms to improve diagnostics and automate workflows. This positions the company as a key innovator in shaping the digitalization and future of healthcare.
The 360 Quadrant maps the ASEAN Point of Care Diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the ASEAN Point of Care Diagnostics quadrant. The top criteria for product footprint evaluation included Product [Infectious Disease Testing Products (HIV Testing Products, Respiratory Infection Testing Products [TB Testing Products, Influenza Testing Products, Other Respiratory Infection Testing Products], Mosquito-borne Disease Testing Products, STD Testing Products, Hepatitis Testing Products [Hepatitis B Testing Products, Hepatitis C Testing Products], HAI Testing Products, Other Infectious Disease Testing Products), COVID-19 Testing Products, Glucose Monitoring Products (Glucose Test Strips, Glucometers, Lancets), Cardiometabolic Testing Products (Cardiac Marker Testing Products, HBA1C Testing Products, Blood Gas & Electrolyte Testing Products), Coagulation Monitoring Products, Pregnancy & Fertility Testing Products, Urinalysis Testing Products, Cancer Marker Testing Products, Cholesterol Testing Products, Hematology Testing Products, Fecal Occult Testing Products, Drugs-of-abuse Testing Products, Other POC Products], Technology [Lateral Flow Assays (Immunoassays), Rapid Tests (Molecular Diagnostics), Biochemistry], End User [Clinical Laboratories, Hospitals and Critical Care Centers, Outpatient Settings and Ambulatory Care Centers, Home Care Settings, Other End Users].
Key Players:
Major vendors in the ASEAN Point of Care Diagnostics market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), and ARKRAY, Inc. (US). The key strategies major vendors implement in the ASEAN Point of Care Diagnostics market are partnerships, collaborations, product launches, and product enhancements.
Abbott
Abbott is a leading diversified global healthcare company with strong market positions in diagnostics, medical devices, nutrition, and established pharmaceuticals. It is renowned for its market-leading Freestyle Libre glucose monitoring system, Alinity diagnostic platforms, and cardiovascular devices. Strategically, Abbott is focused on driving growth through continuous innovation in its medical device and diagnostics portfolios, particularly in diabetes care and structural heart. This approach, combined with its strong presence in emerging markets like India, ensures its continued influence on global health and wellness.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche is a global pioneer in healthcare, uniquely positioned with world-leading divisions in both Pharmaceuticals and Diagnostics. The Swiss company is a powerhouse in oncology and immunology and is the global market leader in in-vitro diagnostics with its cobas® platforms. Roche’s core strategy is ""Personalized Healthcare,"" leveraging insights from its diagnostics business to develop targeted therapies and guide clinical decisions. By combining these synergistic strengths, Roche continues to drive medical innovation and shape the future of individualized patient care worldwide.
Siemens Healthineers AG
Siemens Healthineers is a leading global medical technology company with dominant positions in diagnostic imaging, laboratory diagnostics, and cancer care. Following its transformative acquisition of Varian, the German firm now offers a uniquely comprehensive portfolio, from MRI and CT scanners to advanced radiation therapy systems. Its strategy focuses on integrating these capabilities to create end-to-end solutions, particularly in oncology, while embedding AI across its platforms to improve diagnostics and automate workflows. This positions the company as a key innovator in shaping the digitalization and future of healthcare.
Table of Contents
145 Pages
- 1 Introduction
- 1.1 Market Definition
- 1.2 Key Stakeholders
- 2 Executive Summary
- 3 Market Overview
- 3.1 Introduction
- 3.2 Market Dynamics
- 3.2.1 Drivers
- 3.2.1.1 Rising Incidence Of Infectious Diseases
- 3.2.1.2 Increasing Prevalence Of Chronic Diseases
- 3.2.1.3 Favorable Government Initiatives For Poc Testing
- 3.2.1.4 Rising Number Of Public-private Partnerships (Ppps)
- 3.2.2 Restraints
- 3.2.2.1 Pricing Pressure On Manufacturers
- 3.2.2.2 Stringent Regulatory Approval Process For Product Commercialization
- 3.2.3 Opportunities
- 3.2.3.1 Gradual Shift Toward Decentralized Healthcare Systems
- 3.2.3.2 Availability Of Poc Tests With Multiplexing Capabilities
- 3.2.4 Challenges
- 3.2.4.1 Shortage Of Skilled Healthcare Providers
- 3.2.4.2 Premium Pricing Of Novel Platforms
- 3.3 Trends/Disruptions Impacting Customers’ Businesses
- 3.4 Value Chain Analysis
- 3.5 Supply Chain Analysis
- 3.6 Ecosystem Analysis
- 3.7 Technology Analysis
- 3.7.1 Key Technologies
- 3.7.1.1 Lateral Flow Assays
- 3.7.2 Complementary Technologies
- 3.7.2.1 Molecular Diagnostics
- 3.7.3 Adjacent Technologies
- 3.7.3.1 Biochemical Technologies
- 3.8 Patent Analysis
- 3.9 Key Conferences & Events, 2025–2026
- 3.10 Porter’s Five Forces Analysis
- 3.10.1 Threat Of New Entrants
- 3.10.2 Threat Of Substitutes
- 3.10.3 Bargaining Power Of Buyers
- 3.10.4 Bargaining Power Of Suppliers
- 3.10.5 Intensity Of Competitive Rivalry
- 3.11 Impact Of Ai On Asean Point Of Care Diagnostics Market
- 3.11.1 Introduction
- 3.11.2 Market Potential Of Ai In Poc Diagnostic Applications
- 3.11.3 Ai Use Cases
- 3.11.4 Key Companies Implementing Ai
- 3.11.5 Future Of Ai In Asean Point Of Care Diagnostics Market
- 4 Competitive Landscape
- 4.1 Introduction
- 4.2 Key Player Strategies/Right To Win
- 4.2.1 Overview Of Strategies Adopted By Players In Asean Point Of Care Diagnostics Market
- 4.3 Revenue Analysis, 2022–2024
- 4.4 Market Share Analysis, 2024
- 4.5 Company Evaluation Matrix: Key Players, 2024
- 4.5.1 Stars
- 4.5.2 Emerging Leaders
- 4.5.3 Pervasive Players
- 4.5.4 Participants
- 4.5.5 Company Footprint, Key Players, 2024
- 4.5.5.1 Company Footprint
- 4.5.5.2 Country Footprint
- 4.5.5.3 Product Footprint
- 4.5.5.4 Technology Footprint
- 4.6 Company Evaluation Matrix: Startups/Smes, 2024
- 4.6.1 Progressive Companies
- 4.6.2 Responsive Companies
- 4.6.3 Dynamic Companies
- 4.6.4 Starting Blocks
- 4.6.5 Competitive Benchmarking: Startups/Smes, 2024
- 4.6.5.1 Detailed List Of Key Startups/Smes
- 4.6.5.2 Competitive Benchmarking Of Key Startups/Smes, By Technology
- 4.6.5.3 Competitive Benchmarking Of Key Startups/Smes, By Country
- 4.7 Company Valuation & Financial Metrics
- 4.7.1 Financial Metrics
- 4.7.2 Company Valuation
- 4.8 Brand/Product Comparison
- 4.9 Competitive Scenario
- 4.9.1 Product Launches & Approvals
- 4.9.2 Deals
- 4.9.3 Expansions
- 5 Company Profiles
- 5.1 Key Players
- 5.1.1 Abbott
- 5.1.1.1 Business Overview
- 5.1.1.2 Products Offered
- 5.1.1.3 Recent Developments
- 5.1.1.3.1 Product Approvals
- 5.1.1.3.2 Deals
- 5.1.1.4 Mnm View
- 5.1.1.4.1 Key Strengths
- 5.1.1.4.2 Strategic Choices
- 5.1.1.4.3 Weaknesses & Competitive Threats
- 5.1.2 F. Hoffmann-la Roche Ltd.
- 5.1.2.1 Business Overview
- 5.1.2.2 Products Offered
- 5.1.2.3 Recent Developments
- 5.1.2.3.1 Product Launches & Approvals
- 5.1.2.3.2 Deals
- 5.1.2.4 Mnm View
- 5.1.2.4.1 Key Strengths
- 5.1.2.4.2 Strategic Choices
- 5.1.2.4.3 Weaknesses & Competitive Threats
- 5.1.3 Siemens Healthineers Ag
- 5.1.3.1 Business Overview
- 5.1.3.2 Products Offered
- 5.1.3.3 Recent Developments
- 5.1.3.3.1 Product Approvals
- 5.1.3.3.2 Deals
- 5.1.3.3.3 Expansions
- 5.1.3.4 Mnm View
- 5.1.3.4.1 Key Strengths
- 5.1.3.4.2 Strategic Choices
- 5.1.3.4.3 Weaknesses & Competitive Threats
- 5.1.4 Sysmex Corporation
- 5.1.4.1 Business Overview
- 5.1.4.2 Products Offered
- 5.1.4.3 Recent Developments
- 5.1.4.3.1 Expansions
- 5.1.4.4 Mnm View
- 5.1.4.4.1 Key Strengths
- 5.1.4.4.2 Strategic Choices
- 5.1.4.4.3 Weaknesses & Competitive Threats
- 5.1.5 Danaher Corporation
- 5.1.5.1 Business Overview
- 5.1.5.2 Products Offered
- 5.1.5.3 Mnm View
- 5.1.5.3.1 Key Strengths
- 5.1.5.3.2 Strategic Choices
- 5.1.5.3.3 Weaknesses And Competitive Threats
- 5.1.6 Bd
- 5.1.6.1 Business Overview
- 5.1.6.2 Products Offered
- 5.1.6.3 Recent Developments
- 5.1.6.3.1 Deals
- 5.1.6.3.2 Expansions
- 5.1.7 Quidelortho Corporation
- 5.1.7.1 Business Overview
- 5.1.7.2 Recent Developments
- 5.1.7.2.1 Product Approvals
- 5.1.7.2.2 Deals
- 5.1.7.2.3 Expansions
- 5.1.8 Cardinal Health
- 5.1.8.1 Business Overview
- 5.1.8.2 Products Offered
- 5.1.8.3 Recent Developments
- 5.1.8.3.1 Deals
- 5.1.8.3.2 Expansions
- 5.1.9 Biomérieux
- 5.1.9.1 Business Overview
- 5.1.9.2 Products Offered
- 5.1.9.3 Recent Developments
- 5.1.9.3.1 Product Approvals
- 5.1.9.3.2 Deals
- 5.1.10 Ekf Diagnostics Holdings Plc
- 5.1.10.1 Business Overview
- 5.1.10.2 Products Offered
- 5.1.10.3 Recent Developments
- 5.1.10.3.1 Product Launches
- 5.1.10.3.2 Deals
- 5.1.10.3.3 Expansions
- 5.1.11 Thermo Fisher Scientific Inc.
- 5.1.11.1 Business Overview
- 5.1.11.2 Products Offered
- 5.1.11.3 Recent Developments
- 5.1.11.3.1 Product Launches
- 5.1.11.3.2 Deals
- 5.1.12 Accubiotech, Co., Ltd.
- 5.1.12.1 Business Overview
- 5.1.12.2 Products Offered
- 5.1.12.3 Recent Developments
- 5.1.12.3.1 Product Approvals
- 5.2 Other Players
- 5.2.1 Biosynex Sa
- 5.2.2 Sd Biosensor, Inc.
- 5.2.3 Sekisui Diagnostics
- 5.2.4 Werfen
- 5.2.5 Trinity Biotech
- 5.2.6 Pts Diagnostics
- 5.2.7 Lifescan Ip Holdings, Llc
- 5.2.8 Ctk Biotech, Inc.
- 5.2.9 Wondfo
- 5.2.10 Arkray, Inc.
- 5.2.11 Xiamen Boson Biotech Co., Ltd.
- 5.2.12 Credo Diagnostics Biomedical Pte. Ltd.
- 5.2.13 Anbio Biotechnology Inc.
- 5.2.14 Sg Diagnostics
- 6 Appendix
- 6.1 Research Methodology
- 6.1.1 Research Data
- 6.1.1.1 Secondary Data
- 6.1.1.2 Primary Data
- 6.1.2 Research Assumptions
- 6.1.3 Research Limitations
- 6.1.4 Risk Assessment
- 6.2 Company Evaluation Matrix: Methodology
- 6.3 Author Details
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
